Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores: Marcé, Sílvia, Xicoy, Blanca, García, Olga, Cabezón, Marta, Estrada, Natalia, Vélez, Patricia, Boqué, Concepción, Sagüés, Miguel, Angona, Anna, Teruel Montoya, Raúl, Ferrer Marín, Francisca, Amat, Paula, Hernández Boluda, Juan, Ibarra, Mariana, Anguita Mandly, Eduardo Luis, Cortés, Montserrat, Fernández Ruiz, Andrés, Fontanals, Sandra, Zamora, Lurdes
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/4786
Acceso en línea:https://hdl.handle.net/20.500.14352/4786
Access Level:acceso abierto
Palabra clave:Chronic myeloid leukemia
BCR-ABL1 transcripts
Response to imatinib
Survival
Discontinuation
Relapse-free survival
Hematología
Oncología
3205.04 Hematología
3201.01 Oncología
Descripción
Sumario:The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.

Similares en LA Referencia